nature portfolio

Corresponding author(s):	M. Kevin Brown and Thomas Fessard
Last updated by author(s):	09-02-22

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics				
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.				
n/a Confirmed				
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement				
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly				
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
A description of all covariates tested				
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)				
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.				
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated				
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.				
Software and code				
Policy information about <u>availability of computer code</u>				
Data collection N/A				
Data analysis N/A				
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.				

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Experimental procedures, analytical data for all new compounds. The material is available free of charge

Human rese	earch par	ticipants	
Policy information	about <u>studies</u>	involving human research participants and Sex and Gender in Research.	
Reporting on sex a	and gender	N/A	
Population charac	_	N/A	
Recruitment		N/A	
Ethics oversight	ation on the on	N/A proval of the study protocol must also be provided in the manuscript.	
Note that full inform	iation on the ap	proval of the study protocol must also be provided in the manuscript.	
Field and	ocific r	operting	
		eporting	
	one below that	t is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.	
Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences			
For a reference copy of	the document wit	th all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>	
Life sciei	nces st	audy design	
All studies must di	isclose on thes	e points even when the disclosure is negative.	
Sample size	6		
Data exclusions	no data was e	excluded	
Replication	none		
Randomization	N/A		
Blinding	N/A		
Reportin	ng for s	pecific materials, systems and methods	
		rs about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
system of method is	sted is relevant t	o your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.	
Materials & experimental systems Methods			
n/a Involved in the study n/a Involved in the study			
X Antibodies X ChIP-seq			
Palaeontology and archaeology MRI-based neuroimaging Animals and other organisms			

Clinical data

Dual use research of concern

Eukaryotic cell lines

Policy information about <u>cell lines and Sex and Gender in Research</u>

Cell line source(s)

MDCK-KO cell line was generated internally at Novartis according to J. Pharm. Sci. 2021, 110, 2562

Authentication

no further identification was done after receipt of the cells

Mycoplasma contamination

not tested

Commonly misidentified lines (See <u>ICLAC</u> register)

cells used are not on the list of commonly misidentified cells